Difference between revisions of "Pharmacy"

Latest revision as of 05:55, 29 April 2013

Below are listed some of the common drugs used in canine medicine. See the FDA Green book for a comprehensive list of approved veterinary medicines.

Drug	Indications	Dose	Route	Frequency
Acarbose	Diabetes mellitus	12.5 - 20 mg	Oral	with each meal
Acemannan	Immunomodulation	1 - 2 mg/kg	Intralesional, IP or SQ	weekly
Acepromazine	Sedation, restraint	0.05 - 2.25 mg/kg	SQ, IM, PO	q 8 - 12hrs
	Aortic thromboembolism	0.15 - 0.3 mg/kg	SQ	q 8 - 12hrs
	Amphetamine and pseudoephedrine toxicosis	0.05 -1.0 mg/kg	IV, IM, SQ	q 8 - 12hrs
Acetazolamide	Glaucoma	5 - 10 mg/kg	PO	q 8 - 12hrs
Acetylcysteine	Mucolytic (Asthma), Acetaminophen toxicity	140 mg/kg	IV	loading dose
		5 - 10 mg/kg	PO	every 12 hours
Acetylsalicylic acid	Antipyretic	6 - 10 mg/kg	PO	q 48 - 72hrs
	Antithrombotic	25 mg/kg	PO	2 times/wk
	Anti-inflammatory	10 - 20 mg/kg	PO	q 48 hrs
	Analgesia	10 mg/kg	PO	q 48hrs
Actinomycin D	Chemotherapy / antimicrobial	0.5 - 0.9 mg/m²	IV	once every 3 weeks
S-Adenosylmethionine	Glutathione replenisher - chronic hepatitis, hepatic encephalopathy, portosystemic shunt	20 - 30 mg/kg	PO	q 24hrs
Aglepristone	Mesalliance	10mg/kg	SQ	stat
Albendazole	Lungworm	50 mg/kg	PO	daily for 21 days
Albuterol sulphate	Bronchodilation	90 µg metered dose	inhaler	q 6 - 8hrs
Alfaxan	general anesthesia	1 - 2 mL per 5 kg bodyweight	IV	bolus or slowly IV
Allopurinol	Urate uroliths	10 mg/kg	PO	q 8 - 12hrs for 30 days
Alprazolam	Anxiolytic	0.125 - 0.25 mg/dog	PO	q 12hrs
Aluminium carbonate gel	Phosphate binder	10 - 30 mg/kg	PO with meals	q 8hrs
Aluminium hydroxide	Antacid	20 - 30 ml	PO	q 2 - 4 hrs
	Phosphate binder	30 - 90 mg/kg	PO with meals	q 8 - 24 hrs
Amantadine	Analgesia for chronic pain	3 - 5 mg/kg	PO	daily for 7 - 14 days
Amikacin	Susceptible infections	15 - 22 mg/kg	IM, IV, SQ	q 24hrs
Aminophylline	Asthma	4 - 6.6 mg/kg	PO	q 8 - 12hrs
		2 - 5 mg/kg	IV infusion	q 12hrs
5-aminosalicylic acid	ulcerative colitis	20 mg/kg	PO	q 24 hrs
Amitriptyline (Endep-10)	Analgesia	2 mg/kg	PO	q 24 hrs
Amlodipine besylate	Systemic hypertension	0.625 mg	PO	q 24 hrs
Ammonium chloride	Struvite dissolution	800 mg	PO	q 24 hrs
Amoxicillin/clavulanate	Susceptible infections	10 - 20 mg/kg	PO	q 12 hrs
Amoxil	Susceptible infections	4 - 11 mg/kg	PO	q 12 hrs
Amphetamine	CNS stimulation during certain toxicoses	5 mg	PO	q 12 hrs
Amphotericin B	Systemic mycoses	0.15 - 1 mg/kg in 5% dextrose	IV	q 48 hrs to a total cumulative dose of 10mg/kg
			SQ	diluted 1:10 in saline
Ampicillin	Susceptible infections	20 - 60 mg/kg	PO	q 8 - 12 hrs
Amprolium	Coccidiosis	60 - 100 mg/kg	PO	q 24 hrs x 5 d
	With sulfadimethoxine	150 mg/kg	PO	q 24 hrs x 5d
Ascorbic acid	Antioxidant	25 - 125 mg/kg/day	PO	q 24hrs
	Acetaminophen toxicosis	30 mg/kg	PO, SQ	6 - 7 treatments
Asparaginase	Lymphosarcoma	10,000 U/m²	IV	weekly as part of a protocol
Aspirin	Antipyretic	6 - 10 mg/kg	PO	q 48 - 72hrs
Atenolol	ß₁-blocker for Hypertrophic cardiomyopathy + Hypertension	6.25 mg/cat	PO	q 24hrs
Atipamezole	Medetomidine reversal	equivolume	IM	as needed
Atovaquone	Toxoplasma spp, Babesia spp, Pneumocystis spp	10 - 15 mg/kg with fatty meal	PO	q 8 hrs x 21 days
Atracurium	Paralytic anaesthetic agent	0.1 - 0.25 mg/kg	IV	repeated q 30mins
Atropine	Pre-anaesthetic medicant, Sinus bradycardia	0.02 - 0.04 mg/kg	IM, IV, SQ	as required
	Organophosphate toxicity	0.2 - 2.0 mg/kg	IM, SQ	q 2hrs
Aurothioglucose	Pemphigus, periodontitis and pododermatitis	1 - 2 mg	IM	weekly
Azathioprine	Enteritis	0.2 -0.3 mg/kg	PO	q 24 - 48hrs
	Immune-mediated haemolytic anaemia	1 mg/kg	PO	q 24 - 48hrs
	Immunosuppression	1.1 mg/kg	PO	q 48hrs
Azithromycin	Susceptible infections	5 mg/kg	PO	q 24 - 48 hrs
	Susceptible infections	80 mg stat	PO	weekly x 3
Azodyl	Probiotic	1 capsule	PO	q 12 - 24 hrs
Aztreonam	Susceptible infections	12 - 25 mg/kg	IV, IM	q 8 - 12 hrs
Baytril	Susceptible infections	5.0 - 20.0 mg/kg	PO, SQ, IM, IV (with caution - may cause blindness)	q 24hrsfor 7 - 10 days
Beclomethasone	Anti-inflammatory	200 mg	Inhalant	as required
Benazepril	Afterload reduction (chronic renal disease, congestive heart failure)	0.25 - 0.5 mg/kg	PO	q 24hrs
Benzimidazole	Trypanosomiasis	5 mg/kg	PO	q 24hrs for 4 months
Benzocaine	Local anaesthetic	1 - 5 ml	SQ	as required
Benzoyl peroxide	Seborrhoea, antibacterial	leave on skin for 10mins		q 3 - 4 days for 2 weeks
Betamethasone	Anti-inflammatory	0.1 - 0.2 mg/kg	PO	q 12 - 24hrs
Bethanechol	Bladder atony, dysautonomia, cystitis	1.25 - 5.0 mg	PO	q 8- 12 hrs
Bisacodyl	Constipation	2 - 5 mg/dog	PO	q 24hrs as needed
Bleomycin	Chemotherapy	10 µg/m²	IV, SQ	q 24hrs for 4 days, then weekly; max dose 200mg/m²
Bran	Stool softener	1 - 2 teaspoons/400g food	PO	as needed
Brewer's yeast	B vitamin source	0.2 mg	PO	q 24 hrs
Bromhexine hydrochloride	Mucolytic for asthma	2 mg/kg	PO	q 12 hrs for 7 - 10 days
Bromide	Anticonvulsant	30 - 60 mg/kg	PO	q 12 hrs
Bromocriptine	Cushing's syndrome, False pregnancy, lactation cessation	10 - 30 µg/kg	PO	q 24 hrs for 10 - 16 days
Budesonide	Asthma, ulcerative colitis	1 mg/dog	PO	daily
Bunamidine	Cestodes - Taenia spp, Spirometra spp, Diphyllobothrium spp	20 - 50 mg/kg	PO	after 3 hr fast
Bupivicaine hydrochloride	Local Anaesthetic	0.22 - 3.0 ml/cat	Epidural	stat
Buprenorphine	Opioid analgesia	0.005 - 0.01 mg/kg	IV, IM	q 4 - 8 hrs
Buspirone	Behavioural therapy	0.5 - 1.0 mg/kg	PO	q12-24hrs
Busulfan	Chronic myelocytic leukaemia	3 - 4mg/m² or 0.1 mg/kg	PO	q 24 hrs
Butorphanol	Preanesthetic	0.05 - 0.4mg/kg with ACP	IV, IM, SQ
	Antiemetic	0.2 - 0.6 mg/kg	SQ, IM, IV
	Analgesia	0.1 - 0.8 mg/kg	PO	q 6 - 12 hrs
Cabergoline	Induction of estrus/abortion/pyometra	5 μg/kg/day	PO, SQ	q 24 hrs
Calcitriol	Hypoparathyroidism, hyperparathyroidism	1.5 - 3.0 ng/kg	PO	q 24 hrs
Calcium carbonate	Nutritional supplement	1/2 tsp	PO	daily
	Phosphate binder	60 - 100 mg/kg	PO	daily
Calcium chloride 10%	Ventricular asystole	1 ml/9kg or 0.1 - 0.3ml/kg	IV (slowly)	stat
	Hypocalcaemia	1 ml/9kg	IV	stat
Calcium citrate	Calcium replacement, cystitis	10 - 30 mg/kg	PO	q 8 hrs
Calcium EDTA	Lead poisoning	100 mg/kg/day	SQ	daily for 5 days
Calcium gluconate	Ventricular asystole	0.5 - 1.5 ml/kg	IV (slowly)	as required
	Hypocalcemia, hyperkalemia	0.5 - 1.5 ml/kg	IV (slowly)	as required
Capstar	Fleas	1 tab	PO	daily as needed
Captopril	Vasodilator	2 - 3 mg/dog	PO	q 8 - 12 hrs
		3 - 6.25 mg/dog	PO	q 12 hrs
Carbenicillin	cystitis	10 - 55 mg/kg	PO	q 8hrs
Carboplatin	Chemotherapy	200 mg/m²	IV	q 4 weeks
Carmustine	Chemotherapy	50 mg/m²	IV	q 6 weeks
Carprofen	Analgesia	1 - 4 mg/kg	SQ	stat
		0.5-1.0 mg/kg	PO	q 24hrs
Cartrofen	Analgesia	1 - 4 mg/kg	SQ	stat
Cefadroxil	Susceptible infections	10 mg/kg	PO	q 24 hrs for 1 - 4 weeks
Cefovecin	Susceptible infections	8 mg/kg (0.5 cc)	SQ	q 2 weeks x 3
Cephalexin	Susceptible infections	10 - 35 mg/kg	PO	q 8 - 12 hrs
Cerenia	Anti-emetic	1.0 mg/kg	SQ/PO	q 24 hrs for 4 days, then rest 2 days
Charcoal, activated	Adsorbent for poisonings	1 - 8 g/kg	PO	as needed
Chlorambucil	Chemotherapy, ulcerative colitis	0.1 - 0.5 mg/kg	PO	q 48 - 72 hrs
	pemphigus	0.1 - 0.2 mg/kg	PO	q 48 hrs with prednisolone
Chloramphenicol	Susceptible infections	10 mg/kg	PO	q 12hrs
Chlorhexidine 0.5%	Burns	dilute 1:40 with saline	topically	q 24hrs
Chlorothiazide	Diuretic	10 - 40 mg/kg	PO	q 12 hrs
	Partial ADH deficiency	20 - 40 mg/kg	PO	q 12 hrs
Chlorpheniramine	Antihistamine	1 - 2 mg/dog	PO	q 8 - 12 hrs
Chlorpromazine	vomiting, pancreatitis	0.2 - 0.5 mg/kg	IM or SQ	q 6-8hrs
Cholecalciferol (Vit D)	hyperparathyroidism, hypocalcaemia	500 - 2000 U/kg	PO	q 24 hrs
Chondroitin	Arthritis	50 - 100 mg/dog	PO	q 24 hrs
Cimetidine	Oesophagitis, antiemetic, gastritis	5 - 15 mg/kg	PO, IV, IM	q 8 - 12 hrs
Ciprofloxacin	Susceptible infections	11 - 15 mg/kg	PO	q 24 hrs
Cisapride (Prepulsid)	constipation, megacolon	0.5 - 5.0mg/cat	PO	q 12 hrs
Cisplatin	Chemotherapy	100 mg/m²	IV	q 4 weeks x 2
Clarithromycin	Mycobacterium spp	50 mg/dog	PO	q 12 hrs
Clavulox	Susceptible infections	10 - 20 mg/kg	PO	q 12 hrs
Clindamycin	Anaerobic infections	5 - 11 mg/kg	PO	q 12 hrs
	Stomatitis, Pancreatitis	22 mg/kg	PO	q 24 hrs
	Exocrine pancreatic insufficiency	5 - 10 mg/kg	PO	q 6 - 8 hrs
	Enteroepithelial cycle	12.5 - 50 mg/kg	PO	q 12 hrs
Clofazimine	Mycobacterium spp	4 - 8 mg/kg	PO	q 24 hrs for 6 weeks
		50 mg/cat	PO	q 48 hrs
Clomipramine	obsessive compulsive disorders, aggression	0.5 - 2.0 mg/kg	PO	q 12 - 24 hrs
Clonazepam	Seizures, obsessive compulsive disorders, separation anxiety	0.5 mg/kg	PO	q 8 - 12 hrs
Clopidogrel	thromboembolism, hypertrophic cardiomyopathy	18.75 - 75 mg	PO	q 24 hrs
Clorazepate	separation anxiety	1 - 2 mg/kg	PO	q 8 - 12 hrs
Clotrimazole	Fungal infections	apply to lesion	topical	q 12 hrs
	Fungal infections	60 ml of 1 g/dL of polyethylene glycol intranasal		over 1 hr under general anaesthesia
Cloxacillin	Susceptible infections	20 - 40 mg/kg	PO, IM, IV	q 4 - 8 hrs
Coal tar shampoos	Seborrhoea	Keep in contact with skin for 10 mins	Topically	q 24 hrs
Cobalamin	see Vit B12
Cod liver oil		1 teaspoon / 10 kg
Codeine	Pain relief	0.5 - 4 mg/kg	PO	q 6 - 12 hrs
	Antitussive, analgesia	0.1 - 0.3 mg/kg	PO	q 4 - 6 hrs
Colchicine	Antifibrotic	0.01 - 0.3 mg/kg	PO	q 4 - 6 hrs
Colony stimulating factor	cyclic neutropenia	2.5 - 5.0 mg/kg (3 × 10⁷ IU/kg)	SQ	q 24 hrs
Convenia	Susceptible infections	8 mg/kg (0.5 cc)	SQ	q 2 weeks x 3
Corticotrophin gel (ACTH)	Response test	pre-ACTH sample 0.5 - 2.2 IU/kg	IM
Cortisone acetate	hypoadrenocorticism	1 mg/kg	PO, IM	q 24 hrs
Cosyntropin	pre-ACTH sample	0.125 mg/dog	IV
Cyanocobalamin	Vit B₁₂ deficiency	50 - 1000 µg	PO, IM, SQ	q 24 hrs
Cyclizine	Antiemetic	4 mg/kg	IM	q 8 hrs
Cyclophosphamide	Chemotherapy	100 mg/m²	PO	q 3 weeks with doxorubicin
Cyclosporin	thrombocytopenia, pemphigus, sebaceous adenitis	4 - 6 mg/kg	4hr IV infusion	q 24 hrs (avoid extravasation)
		3 - 7 mg/kg	PO	q 12 hrs
Cyclosporin ophthalmic	keratoconjunctivitis sicca	1 - 2% solution	drop in eye	q 12 hrs
Cyclothiazide	diuretic	0.5 - 1.0 mg/kg	PO	q 24 hrs
Cytarabine	Chemotherapy	30-50 mg/kg	IV, IM, SQ	once a week
		100 mg/m²	IV. IM, SQ	q 24 hrs for 4 days then
		20 mg/m²	Intrathecal	q 24 hrs for 1 - 5 days
Dacarbazine	Lymphoreticular neoplasms	200 - 250 mg/m²	IV	q 24 hrs for 5 days, every 21 days
	Soft tissue sarcomas	1000 mg/m²	IV infusion	over 6 - 8hrs, every 21 days
Dactinomycin	Chemotherapy	0.015 mg/kg	IV	q 24 hrs for 3 - 5 days, wait 3 weeks then
		0.1 - 1.5 mg/m²	IV	weekly
Dalteparin	DIC, Thrombosis	70 IU/kg	SQ	q 24 hrs
Dapsone	Mycobacterium spp	1.1 mg/kg	PO	q 12 hrs for 4 - 6 weeks
Deferoxamine mesylate	Iron chelator	10 mg/kg	IV, IM, SQ	q 2 hrs for 2 doses then q 8 hrs for 24 hrs
	Reperfusion (ischaemia) injuries	50 mg/kg	IV	over 5 mins
Deprenyl	hyperadrenocorticism	1 - 2 mg/kg	PO	q 24 hrs
Desmopressin acetate	diabetes insipidus	0.3 µg/kg	IM	q 12 - 24 hrs
Desoxycorticosterone acetate	hypoadrenocorticism	0.2-0.4 mg/kg	conjunctivally	q 24hrs, max 5mg
Desoxycorticosterone pivalate	hypoadrenocorticism	25 mg	IM	stat
Dexamethasone	central oedema, spinal cord trauma, DJD, other CNS trauma	2 mg/kg	IV	then,
		1 mg/kg	IV, SQ	q 8 - 12 hrs, then
		0.1 mg/kg	IV, SQ, PO	q 8-12hrs
	hydrocephalus	0.25 mg/kg	IV, IM, PO	q 6 - 8 hrs
	shock, anaphylaxis	4 - 6 mg/kg	IV (slowly)
	immune-mediated disease	0.25 - 1.25 mg/kg	PO	q 12 - 24 hrs
		0.1 - 0.15 mg/kg	SQ, PO	q 12 hrs for 5 - 7 days, then taper dose
	hypoadrenocorticism	0.1 - 0.5 mg/kg	SQ, IV	with mineralocorticoids
	asthma	1 mg/kg	IV	then
		0.25 - 1.0 mg/cat	PO	q 8 - 24hrs
Dexrazoxane	iron chelation for doxorubicin-induced cardiotoxicity	25 mg/kg (ratio of 10-20:1 dexrazoxane : doxorubicin)	IV	15 mins before doxorubicin
Dextran 40	Shock	10 - 20 ml/kg	IV	q 24 hrs
Dextran 70	Volume expander	10 - 20 ml/kg	IV	q 24 hrs to effect
Dextromethorphan	coughing	0.5 - 2.0 mg/kg	PO, SQ, IV	q 6 - 8 hrs
Dextrose, 50%	hypoglycemia, insulin overdose	2 ml/kg	PO
		0.25 - 1.0 ml/kg	IV
Dextrose, 5%	hypoglycemia, insulin overdose	40 - 50 ml/kg	IV, SQ, IP	as needed
Diazepam	Pre-med, Behavior modification	0.5 - 2.2 mg/kg	PO	as needed
	seizures	0.15 - 0.70 mg/kg	PO, IV	q 8 hrs
	status epilepticus, toxins	0.5 - 1.0 mg/kg	IV	in increments of 5 - 20 mg
	strychnine-induced seizures	2 - 5 mg/kg	IV	as needed
		0.5 mg/kg	IV
Dichlorphenamide	Glaucoma	3 - 5 mg/kg	PO	q 8- 12 hrs
Dicloxacillin	Susceptible infections	10 - 50 mg/kg	PO	q 6 - 8 hrs
Diethylcarbamazine	heartworm disease	6.6 mg/kg	PO	q 24 hrs
Diethylstilboestrol	incontinence	0.01-0.02 mg/kg	PO	q 24 hrs
Difloxacin	Susceptible infections	5 - 10 mg/kg	PO	q 24 hrs
Digoxin	Congestive heart failure	0.005 - 0.008 mg/kg	PO	q 12 hrs
Dihydrotachysterol	milk fever, hypoparathyroidism	0.03 - 0.06 mg/kg	PO	q 24 hrs for 3, then
		0.01-0.02 mg/kg	PO	q 24hrs
Diltiazem	hypertension, hypertrophic cardiomyopathy, supraventricular tachycardia	0.5 - 2.5 mg/kg	PO	q 8 hrs
Dimenhydrinate	Antihistamine	1.0 - 3.0 mg/kg	PO, IM, IV	as needed
Dimercaprol	Arsenic toxicosis	2.5 -5.0 mg/kg	IM	q 4 hrs for 2 days, then q 8hrs for 3 days, then q 12hrs for 10 days
Dimethylsulfoxide	Spinal cord trauma, amyloidosis	0.5 - 1 g/kg	IV (10%)	q 6 - 8 hrs over 45 min
Diminazine aceturate	Babesia spp, Trypanosoma spp	2.0 - 3.5 mg/kg	IM	Once
		3.5 mg/kg	IM, SQ	q 24 hrs for 2 days
Dinoprost	see prostaglandin F2a
Diphenhydramine	Antihistamine	2 - 4 mg/kg	PO	q 6 - 8 hrs
	mast cell tumour, antiemetic	2 mg/kg	IM, IV	q 12 hrs as needed
Diphenoxylate	ulcerative colitis	0.05 - 0.1 mg/kg	PO	q 12 hrs
Diphenylthiocarbazone	Thallium toxicosis	50 - 70 mg/kg	PO	q 8 hrs
Diphemanil methylsulphate	bronchodilator	1.8 mg/kg	IM	q 12 hrs
Dipyridamole	thromboembolism	4 - 10 mg/kg	PO	q 24 hrs
Disodium EDTA	Calcium keratopathy	0.37% solution	topically	lavage cornea for 15 - 20 mins
Dobutamine	Positive ionotrope	0.5 - 2.0 µg/kg/min	IV infusion (caution)	1 min
Dolasetron	antiemetic	0.6 mg/kg	PO, IV, SQ	q 24 hrs
Dopamine	hypotension, shock, inotropic agent	2 - 25 µg/kg	IV infusion	1 min
Doxapram	Respiratory stimulant in neonates	1 - 5 mg/kg	IV (umbilical vein)	as needed
		1 - 2 drops	PO	as needed
Doxorubicin	chemotherapy	10 - 30 mg/m²	IV	q 21 days
Doxycycline	Susceptible infections	5 - 10 mg/kg	PO, IV	q 12 - 24 hrs
Edrophonium	myasthenia gravis diagnosis	2.5 mg/dog	IV	stat
Emodepside	anthelmintic	1 x vial	topically	monthly
Enalapril	hypertension, congestive heart failure, valvular endocardiosis	0.25 - 0.5 mg/kg	PO	q 12 - 24 hrs
Enilconazole 10%	Aspergillus spp	5% solution (1:1 in water)	topically	q 12 hrs for 7 - 10 days
		10-20 mg/kg (10% solution: 50:50 in water	instil into nasal sinus	q 12hrs for 10 - 14 days
Enrofloxacin	Susceptible infections	5.0 - 20.0 mg/kg	PO, SQ, IM, IV (with caution - may cause blindness)	q 24 hrs for 7 - 10 days
Ephedrine	bronchodilator, incontinence	2.0 - 5.0 mg/kg	PO	q 8 - 12 hrs
Epinephrine	cardiac arrest	0.2 ml/kg	IV, intratracheal	q 5 - 15 min as needed
Epsiprantel	Dipylidium spp, Taenia spp	2.5 - 2.75 mg/kg	PO	stat
Ergocalciferol	Vitamin D	500 - 2000 IU/kg	PO	q 24 hrs
Erythromycin	Susceptible infections	10 - 22 mg/kg	PO, IV	q 8 hrs
Erythropoietin	anemia	50 - 100 IU/kg	SQ	3 x weekly for 12 weeks then twice weekly (as need to maintain PCV at 35%)
		400 IU/kg	IV, SQ	once a week
Esmolol	Selective B₁ blockade	0.05 mg/kg	slow IV	loading dose, then
		50 - 200 µg/kg	IV infusion	per min
Estradiol cypionate	mesalliance	125 - 250 µg	IM	between 40hrs and 5 days post-coitus
Ethosuximide	seizures	40 mg/kg	PO	load, then
		20 mg/kg	PO
EDTA	anticoagulant, chelation	1 mg/kg	IV	q 2hrs
Etidronate disodium	hypercalcaemia	10 mg/kg	PO	q 2 hrs
Etomidate	general anesthesia	0.5 - 3.0 mg/kg	IV	as needed
	With opioids	0.5-1.0 mg/kg	IV	as needed
Etretinate	dermatopathy	1 - 2 mg/kg	PO	q 24 hrs
Famotidine	antacid	0.5 mg/kg	IM, SQ, PO	q 12 - 24 hrs
Febantel	anthelmintic	10 mg/kg per 1mg/kg praziquantel	PO	q 24 hrs for 3 days
Fenbendazole	anthelmintic	25 - 50 mg/kg	PO	q 12 hrs for 3-14 days
Fentanyl	analgesia	0.01 mg/kg	IV, SQ, IM
Fitergol	cognitive dysfunction syndrome	1 - 5 mg/dog	PO	q 24hrs
Flavoxate	Incontinence (Detrusor hyperspasticity)	100 - 200 mg/dog	PO	q 6 - 8 hrs
Florfenicol	Susceptible infections	22 - 50 mg/kg	PO, IM, SC	q 12 hrs
Fluconazole	fungal infections	2.5 - 10.0 mg/kg	PO with food	q 12 - 24 hrs
Flucytosine	Cryptococcus spp	30 - 50 mg/kg	PO	q 6 - 8 hrs
Fludrocortisone	hypoadrenocorticism	0.1 - 0.2 mg/dog	PO	q 24 hrs
Flumazenil	hepatic encephalopathy	0.2 mg/dog	IV	as needed
Flumethasone	anti-inflammatory	0.15 - 0.3 mg/kg	IV, IM, SQ	q 24 hrs
Flunixin meglamine	analgesic, anti-pyretic	0.5 - 2.2 mg/kg	IV, IM, SQ	oid for 3 days, then repeat after 4 days
Fluoxetine	Behavioural problems	0.1 - 2.0 mg/kg	PO	q 24 hrs
Flurazepam	seizures	0.2 - 0.4 mg/kg	PO	q 4 - 7 days
Flurbiprofen	Conjunctivitis	0.2 - 0.4 mg/kg	Topically	q 8 - 12 hrs
Folic acid	Dietary supplement	0.5 - 1.0 mg/kg	PO	q 24 hrs
Follicle stimulating hormone (FSH)	Induction of oestrus	500 IU HCG	IV, IM, SQ	q 24 hrs for 5 days
Fomepizole	Ethylene glycol toxicity	20 mg/kg	IV	stat
Furosemide	diuretic	2 - 4 mg/kg	IV, IM, PO	q 8 - 12 hrs as needed
Gabapentin	Epilepsy	10 mg/kg	PO	q 8 - 12 hrs
Gamma globulin	Immune-mediated disease	1 g/cat	IV	q 6 - 12 hrs
Gentamicin	Susceptible infections	6 - 8 mg/kg	IM, SQ, IV	q 24 hrs
Glimipiride	Non-insulin-dependant diabetes mellitus	0.25 - 0.5 mg/kg	PO	q 24 hrs
Glipizide	Non-insulin-dependant diabetes mellitus	0.25 - 0.5 mg/kg	PO	q 8 - 12 hrs
Glycopyrrolate	Bundle branch block	0.005 - 0.010 mg/kg	IV, IM	as needed
Gold sodium thiomalate	Immune-mediated disease	0.25 - 1.0 mg/kg	IM	weekly x 3; 2nd + 3rd week at 2 - 10 mg/cat
Gonadotropin releasing hormone (GnRH)	Ovarian cystadenoma, detection of ovarian remnant syndrome	25 µg/dog	IM	single treatment
Granisetron	Chemotherapy-associated vomiting	0.1 - 0.5 mg/kg	IV, PO	q 12 - 24 hrs
Granulocyte colony stimulating factor	Neutropenia	3 - 10 µg/kg	SQ	q 12 - 24 hrs
Griseofulvin	Antifungal	10 - 30 mg/kg	PO	q 24 hrs for 4 weeks
Guaifenesin	Tranquiliser	44 - 88 mg/kg	IV	stat
Halofuginone	Coccidiostat, Immunosuppressant	100 µg/kg	PO	q 24 hrs
Halothane	General anesthesia	Induction: 3%	Inhalant	stat
		Maintenance: 0.5-1.5%	Inhalant	as needed
Haemoglobin (polymerised bovine)	Blood replacement	10-30 ml/kg	IV	stat
Heparin	Thromboembolism, thrombophlebitis	Initial dose: 100-200 IU/kg	IV	then
		Maintenance dose: 50-100 IU/kg	SQ	q 6 - 8hrs
	Thromboembolism	Induction 1000 IU/kg	IV	then
		Maintenance: 50 IU/kg	SQ	q 8hrs
	Pancreatitis	50-1000 IU/kg	SQ	q 8 - 12hrs
	DIC	75-100 IU/kg	IV, SQ	q 6hrs
	Lipoprotein lipase provocation test	100 IU/kg	IV	test lipids before and 15 mins after heparin
Heparin, LMW	see Dalteparin
Hetacillin	Susceptible infections	10 - 20 mg/kg	PO	q 8 - 12 hrs not associated with feeding
Hetastarch (Hydroxyethyl starch)	Plasma volume expander	10 - 20 ml/kg	IV	as needed
Human gammaglobulin	Immune-mediated disease	0.5 - 1.5 g/kg	IV	q 12 hrs (infusion)
Hydrocodone	Antitussive	0.22 mg/kg	PO	q 12 hrs
Hyaluronate sodium	Synovitis	0.5 - 1.0 mg/kg	intra-articular	q 7 days
Hydralazine	Vasodilator: congestive heart failure	0.5 mg/kg, titrate up to 0.5 - 0.8 mg/kg	PO	q 12 hrs
Hydrochlorothiazide	Hypertension	0.5 - 2.0 mg/kg	PO	q 12 - 24 hrs
	Nephrogenic diabetes insipidus	0.5 - 5.0 mg/kg	PO	q 12 hrs
	Hypoglycaemia	2 - 4 mg/kg	PO	q 12 hrs
	Calcium oxalate uroliths	2 mg/kg	PO	q 12 hrs
Hydrocortisone	Replacement therapy	0.5 - 1.0 mg/kg	PO	q 24 hrs
	Anti-inflammatory	2.5 - 5.0 mg/kg	PO	q 12 hrs
Hydrocortisone aurate	Hypoadrenocorticism	0.1 - 0.2 mg/kg	IM	q 8 - 12 hrs
	Immune-mediated haemolytic anaemia	2 - 4 mg/kg	IM	q 12 - 24 hrs
Hydrocortisone sodium succinate	Shock	8 - 150 mg/kg	IV	stat
Hydrogen peroxide (3%)	Emetic	5-10 ml/cat	PO	stat
Hydromorphone	Analgesia	0.05 - 0.1 mg/kg	IM, SQ	every 24 hrs
Hydroxyurea	Primary polycythemia	25 - 30 mg/kg	PO	q 3 days
	Chronic granulocytic leukaemia	0.5 g/m²	PO	q 12hrs for 4-6 weeks, then halve dosage
Hydroxyzine	Antihistamine	5-10 mg/cat	PO	q 12hrs
Hypertonic saline	Shock	2-6 ml/kg	rapid IV infusion	stat
Idarubicin HCl	Antiviral	2.0 mg/kg	PO	q 24hrs for 2 days, then repeat q21 days
Idoxuridine	Ocular herpes viral infection	0.1% solution: 1 drop	topically	q 4 - 6 hrs
		0.5% ointment	topically	q 1 hr
Imatinib mesylate	Chemotherapy	10 mg/kg	orally	once daily
Imidacloprid	Fleas	100 mg/ml	topically	0.1 cc/kg monthly
Imidocarb	Ehrlichia spp	5 mg/kg	IM	every 14 days x 2
Imidapril	Congestive heart failure and Chronic renal disease	0.5 mg/kg	PO	q 24hrs
Imipenem-cilastin	Susceptible infections	2 - 10 mg/kg	IM or slow IV	q 6 - 8 hrs
Imipramine	Behavioural modification, urinary incontinence	2.5 - 5.0 mg/cat	PO	q 12 hrs
Insulin, glargine	Diabetes mellitus	0.25-5.0 U/kg	SQ	q 12hrs, adjust as needed
Insulin, lente	Diabetes mellitus	0.5 U/kg	SQ	q 12 - 24hrs
Insulin, NHP	Diabetes mellitus	1 - 3 U/dog	SQ	q 12 - 24hrs
Insulin, PZI	Diabetes mellitus	1 - 3 U/dog	SQ	q 12 - 24 hrs
Insulin, regular	Diabetes mellitus	1 - 2 U/dog	SQ	q 6 - 8 hrs
Insulin, ultralente	Diabetes mellitus	1-3 U/dog	SQ	q 12 - 24hrs
Interferon a₂, human recombinant	Immunostimulant	15 - 30 U/dog	IM, SQ, PO	q 24 hrs on alternate weeks
Iodine	Hyperthyroidism	50 - 100 mg/dog	PO	q 24 hrs
Iodide sodium, potassium 20% solution	Hyperthyroidism	20 mg/kg	PO	q 12 - 24 hrs
Iopamidol	Myelography	0.25 ml/kg	intrathecal	stat
Ipecac syrup	Emetic	2 - 6 ml/dog	PO	stat
Ipodate	Hyperthyroidism (short term)	15 mg/kg	PO	q 12hrs
Iron dextran	anemia	50 mg	IM	at 18 days of age
Isoflurane	Gaseous anaesthesia	Induction: 5% Maintenance: 1.5-2.5%	Inhalation	stat
Isoniazid	Mycobacterium spp	10 - 20 mg/kg	PO	q 24 hrs
Isopropamide	Bundle branch block	0.2 - 0.4 mg/kg	PO	q 8 - 12 hrs
	Antidiarrhoeal, GIT hypermotility	0.2 - 1.0 mg/kg	PO	q 12 hrs
Isoproterenol	Bundle branch block	0.04 - 0.08 µg/kg	IV infusion	as needed
Isosorbide dinitrate	Vasodilator, osmotic diuretic, megaoesophagus	2.5 - 5.0mg	PO	q 12 hrs
Itraconazole	fungal infections	5 - 10 mg/kg	PO	q 12 - 24 hrs
Ivermectin	Heartworm disease prophylaxis	24 µg/kg	PO	once monthly
Kanamycin	Susceptible infections	10 - 15 mg/kg	IV, IM, SQ	q 12 hrs
	GI tract bacterial overgrowth	10 - 12 mg/kg	PO	q 8 - 12 hrs
Kaolin / pectin	GI tract protectant	1 - 2 ml/kg	PO	q 2 - 6 hrs
Ketamine	general anesthesia	7 - 11 mg/kg	IV, IM	stat
Ketoconazole	fungal infections	5.0 - 10.0 mg/kg	PO	q 12 - 24 hrs
Ketoprofen	analgesic	0.2 - 1.0 mg/kg	PO, IM, SQ	q 24 hrs for less than 5 days
L-asparaginase	chemotherapy	10,000 U/m²	IV	weekly as part of a protocol
Lactated Ringer's solution	Rehydration	40 - 50 ml/kg	IV	q 24 hrs
Lactilol	Stool softener, hepatic encephalopathy	250 ml	PO	q 12 hrs
Lactoferrin	periodontitis	40 mg/kg	Topical	q 24 hrs
Lactulose	megacolon, hepatic encephalopathy	2.5-5.0 ml	PO	q 8 - 12 hrs
Lamasil	fungal infections	20 - 30 mg/kg	PO	q 24 hrs for 4 - 10 weeks
Leucovorin	Methotrexate toxicity	3 mg/m²	IM	within 3 hrs of poisoning
Levallorphan	Opioid toxicity/overdose	0.02 - 0.20 mg/kg	IV	as needed
Levamisole	heartworm disease	10 mg/kg	PO	q 24 hrs for 7 days
Levetiracetam	seizures, cognitive disorder	15 - 20 mg/kg	PO	q 8 - 12 hrs
Levodopa	hepatic encephalopathy	6.8 mg/kg initially, then 1.4mg/kg	PO	q 6 hrs
Thyroxine	Hypothyroidism	10-30 µg/kg	PO	q 12hrs
Lidocaine	Ventricular arrhythmias, epidural	0.25 - 1.0 mg/kg	IV, intrathecal	stat
Lime sulphur	Sarcoptes spp	1:40 dilution	Topically	weekly for 6 weeks
Lime water	Alkaline gastric lavage	5 ml/kg	PO	stat
Lincomycin	Susceptible infections	11 - 33 mg/kg	PO, IV, IM	q 12 - 24 hrs
Lisinopril	congestive heart failure, hypertension	0.25 - 5.0 mg/kg	PO	q 24 hrs
Lobaplatin	chemotherapy	35 mg/m²	IV	q 3 hrs
Lomustine

Anonymous

Search

Difference between revisions of "Pharmacy"

Namespaces

More

Page actions

Latest revision as of 05:55, 29 April 2013

@@ Line 172: / Line 172: @@
 |-
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Sulfasalazine|5-aminosalicylic acid]]</font>
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Irritable bowel disease]]</font>
+| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[ulcerative colitis]]</font>
 | width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
@@ Line 443: / Line 443: @@
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Budesonide]]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Asthma]], [[Irritable bowel disease]]</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Asthma]], [[ulcerative colitis]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 mg/dog</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
@@ Line 642: / Line 642: @@
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Chlorambucil]]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Chemotherapy]], [[Irritable bowel disease]]</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Chemotherapy]], [[ulcerative colitis]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1 - 0.5 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
@@ Line 1,890: / Line 1,890: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Imipenem  Imipenem]-cilastin (Broad-spectrum 'Gorilla-cillin')</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Imipenem-cilastin </font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2-10 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2 - 10 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM or slow IV</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Imipramine  Imipramine] </font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Imipramine </font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Behavioural modification, urinary incontinence</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5-5.0 mg/cat</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5 - 5.0 mg/cat</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Insulin]], [[glargine]]</font>
@@ Line 2,115: / Line 2,115: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">as needed</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Levamisole]]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Levamisole</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[heartworm disease]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
@@ Line 2,187: / Line 2,187: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Luteinizing hormone]]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Luteinizing hormone</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Stimulate ovulation</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">50 IU</font>
@@ Line 2,283: / Line 2,283: @@
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 2 weeks, then q 48hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Mepiridine]]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Mepivacaine</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Sedation</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 - 5 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 2 - 4 hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Mepivacaine]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Local [[analgesia]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 - 5 ml of 2% solution</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">as needed</font>
-|-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[Mercaptopurine]]</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[leukemia]], [[lymphoma]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">2 mg/kg</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Meropenem]]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 |-
 | width="20%" height="66" align="left" valign="top" | <font size="2" face="Arial">[[Mesna]]</font>
@@ Line 2,313: / Line 2,295: @@
 | width="20%" height="66" align="left" valign="top" | <font size="2" face="Arial">q 3 hrs x 6 at time of cyclophosphamide treatment, follow with repeat dose (24 hr infusion)</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Metamucil]]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Metamucil</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Laxative</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2-4 g</font>
@@ Line 2,319: / Line 2,301: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Metaproterenol]]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Metaproterenol</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Bronchodilation</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.325 - 0.65 mg/kg</font>
@@ Line 2,325: / Line 2,307: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 4 - 6 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Metaraminol]]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Metaraminol</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Vascular support during shock</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.01 - 0.1 mg/kg</font>
@@ Line 2,337: / Line 2,319: @@
 | width="20%" height="50" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Methazolamide]]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Methazolamide</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[glaucoma]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
@@ Line 2,343: / Line 2,325: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Methenamine hippurate]]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Methicillin </font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Urinary antiseptic</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">250 mg</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs (use with extreme caution)</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Methicillin]] </font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
@@ Line 2,355: / Line 2,331: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Methimazole]]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Methocarbamol]]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hyperthyroidism]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 mg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs, followed by</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Methocarbamol]] (guaifenesin-analogue)</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Muscle relaxation</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">20 - 66 mg/kg</font>
@@ Line 2,367: / Line 2,337: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Methohexital]] </font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Methohexital </font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anaesthesia induction</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5% solution: 11 mg/kg</font>
@@ Line 2,373: / Line 2,343: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 |-
-| width="20%" height="50" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Methotrexate  Methotrexate sodium]</font>
+| width="20%" height="50" align="left" valign="top" | <font size="2" face="Arial">[[Methotrexate]] sodium</font>
 | width="22%" height="50" align="left" valign="top" | <font size="2" face="Arial">[[Chemotherapy]]</font>
 | width="18%" height="50" align="left" valign="top" | <font size="2" face="Arial">2.5 mg/m<sup>2</sup></font>
@@ Line 2,391: / Line 2,361: @@
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Methoxyflurane  Methoxyflurane] </font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Methoxyflurane</font>
 | width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Inhalation anaesthesia</font>
 | width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">Induction: 3%, Maintenance: 0.5-1.5%</font>
@@ Line 2,397: / Line 2,367: @@
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Methscopolamine  Methscopolamine bromide]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Methscopolamine bromide</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anti-emetic</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.3-1.0 mg/kg</font>
@@ Line 2,428: / Line 2,398: @@
 |-
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Methylprednisolone acetate]]</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Eosinophilic granuloma complex|sinophilic ulcers, linear granulomas]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">10-40 mg/cat</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">SQ, IM, intralesional</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 2 weeks x 2 - 6 treatments</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Asthma]]</font>
 | width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
@@ Line 2,445: / Line 2,409: @@
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 - 24 weeks</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Methylprednisolone  Methylprednisolone sodium succinate]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Methyltestosterone</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Spinal trauma</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">15-30 mg/kg</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 2hrs, then q 6hrs for 2 days, then taper dose over 5 - 7 days</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pyrazole  4-Methylpyrazole]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antifreeze toxicity</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" |
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12hrs for 2 days, then</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" |
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">5 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="20" align="left" valign="top" |
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Methyltestosterone  Methyltestosterone]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anabolic steroid</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
 | width="20%" height="34" align="left" valign="top" |
@@ Line 2,481: / Line 2,421: @@
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 48hrs</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Metoclopramide  Metoclopramide]</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Metoclopramide]]</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Gastric motility disorders, antiemetic</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Gastric motility disorders, [[antiemetic]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.2-0.5 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.2  -0.5 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO, IM, SQ</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 |-
 | width="20%" height="20" align="left" valign="top" |
 | width="22%" height="20" align="left" valign="top" |
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1.0-2.0 mg/kg</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1.0 - 2.0 mg/kg</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
 | width="20%" height="20" align="left" valign="top" |
@@ Line 2,499: / Line 2,439: @@
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8hrs, 30 mins before meals</font>
 |-
-| width="20%" height="20" align="left" valign="top" |
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Metoprolol]]</font>
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Dysautonomia|Feline dysautonomia]</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Atrial fibrillation, [[hypertrophic cardiomyopathy]]</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.3 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.05 - 3.0 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
-|-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Metoprolol  Metoprolol] (ß<sub>1</sub>-agonist)</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Atrial fibrillation, [hypertrophiccardiomyopathy.htm  hypertrophic cardiomyopathy]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">2-15 mg/cat</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" |
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">12.5-25.0 mg/cat</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 |-
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Metronidazole]]</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Colitis, [[Coccidiosis]], [[Tritrichomoniasis]], anaerobic infections</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Colitis, [[Coccidiosis]], anaerobic infections</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">10-25 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">10 - 25 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 7 - 14 days</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 7 - 14 days</font>
 |-
 | width="20%" height="20" align="left" valign="top" |
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Gingivitis]]</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">50mg/kg</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">50 mg/kg</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Metyrapone]]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Metyrapone</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Cushing's syndrome]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">65 mg/kg</font>
@@ Line 2,537: / Line 2,465: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Mirtazepine]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antiemetic</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">3mg/cat</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.75 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 3days</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 3 days</font>
 |-
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Misoprostol  Misoprostol] (synthetic PGE<sub>1</sub>)</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Misoprostol]]</font>
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Mucosal protectant</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">3-5 <span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">µg/kg</span></font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">3 - 5 µg/kg</span></font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12hrs as required</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs as required</font>
 |-
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Miconazole  Miconazole]</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">Miconazole cream</font>
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Fungal infections]]</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1-3 cm</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 - 3 cm</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">topically</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 2 - 4 weeks</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 2 - 4 weeks</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [[Midazolam]]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Midazolam]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Preanaesthetic, sedation, </font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.06-0.22 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.06 - 0.22 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
@@ Line 2,567: / Line 2,495: @@
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Milbemycin oxime|Milbemax]]</font>
 | width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Heartworm and intestinal worm prophylaxis</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.5-2.0 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.5 - 2.0 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">monthly</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Silymarin  Milk thistle] (silymarin)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Silymarin]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Free radical scavenger</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">50-250 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">50 - 250 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Mineral oil</font>
@@ Line 2,583: / Line 2,511: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Minocycline  Minocycline] (tetracycline antibiotic)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Mithramycin</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5-15 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Mithramycin  Mithramycin]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hypercalcaemia]], testicular cancer, malignancies</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.25-0.50 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.25 - 0.50 µg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs x 2</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs x 2</font>
 |-
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Mitotane]] (o,p-DDD)</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Pituitary-dependant [[Cushing's syndrome|hyperadrenocorticism]]</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Pituitary-dependant [[hyperadrenocorticism]]</font>
 | width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">25 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 7 days (maintenance)</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" |
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">75-100 mg/kg/week PO</font>
-| width="20%" height="20" align="left" valign="top" |
-| width="20%" height="20" align="left" valign="top" |
 |-
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Mitoxantrone]]</font>
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Anticancer chemotherapy</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">6.0-6.5 mg/m<sup>2</sup></font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">6.0 - 6.5 mg/m<sup>2</sup></font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 3-4 weeks x 4 - 6</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 3 - 4 weeks x 4 - 6</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Morphine]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antitussive, [[analgesia]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.05-0.1 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.05 - 0.1 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">SQ, IM</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 4 - 6hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 4 - 6 hrs</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Moxifloxacin]]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">''[[Mycobacterium spp]]'', ''[[Bartonella henselae infection|Bartonella spp]]''</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">''[[Mycobacterium spp]]'', ''Bartonella spp]]''</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5.0 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hours</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Mycobacterial cell wall extract</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">Naloxone</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Immunostimulation</font>
+| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">stereotypic behaviour</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1.5 ml</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">20 mg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, deep IM</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs x 1</font>
+| width="20%" height="20" align="left" valign="top" |
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Nadolol  Nadolol] (ß<sub>1/2</sub>- antagonist)</font>
+| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hypertension]]</font>
+| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Shock</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.25-0.5 mg/kg</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 1 hr</font>
-|-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nafcillin  Nafcillin] (ß-lactam antibiotic)</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Resistant staphylococcal infections</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO, IM</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nalbuphine  Nalbuphine hydrochloride] (synthetic opioid)</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Analgesia]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.75-1.5 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nalorphine  Nalorphine]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Opioid antagonist</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
-|-
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Naloxone  Naloxone HCl]</font>
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">stereotypic behaviour</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">20 mg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
-| width="20%" height="20" align="left" valign="top" |
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Shock</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 1hr</font>
 |-
 | width="20%" height="20" align="left" valign="top" |
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Opioid antagonist</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.01-0.04 mg/kg</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.01 - 0.04 mg/kg</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">to effect, repeat as needed</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Naltrexone  Naltrexone] (Trexan)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Nandrolone</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Behavioural problems, lick granuloma</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">2.2 mg/kg</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nandrolone  Nandrolone decanoate]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anaemia</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10-50 mg/cat</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.0 - 10 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">weekly</font>
 |-
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Pimaricin|Natamycin]] (Pimaracin)</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[N-acetylcysteine]]</font>
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Ocular fungal infections</font>
+| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">see [[Acetylcysteine]]</font>
-| width="18%" height="20" align="left" valign="top" |
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">topically</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 3 - 8hrs</font>
-|-
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/N-acetylcysteine  N-acetylcysteine]</font>
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">see Acetylcysteine</font>
 | width="18%" height="20" align="left" valign="top" |
 | width="20%" height="20" align="left" valign="top" |
 | width="20%" height="20" align="left" valign="top" |
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Neodarbazine</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Neomycin]]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antiemetic</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">4.5-9.0 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Neomycin  Neomycin]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">7 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, IV, SC</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs (nephrotoxic)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs (nephrotoxic)</font>
 |-
 | width="20%" height="20" align="left" valign="top" |
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Hepatic encephalopathy]]</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">10-20 mg/kg</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">10 - 20 mg/kg</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">per rectum</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 6 hrs</font>
 |-
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Neostigmine]]</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Diagnostic aid for [myasthenia%20gravis.htm  myasthenia gravis]</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Diagnostic aid for [[myasthenia gravis]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">20 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg with 0.04 mg/kg of atropine</font></span>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">20 µg/kg with 0.04 mg/kg of atropine</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
@@ Line 2,727: / Line 2,595: @@
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, divided doses</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Niacin  Niacin] (Niacinamide)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Niacin</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Hypertriglyceridemia</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">50-100 mg/day</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">50 - 100 mg/day</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
-| width="20%" height="20" align="left" valign="top" |
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Nitenpyram]]</font>
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Vacor toxicosis</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Fleas]]</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">500-1000 mg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1 tab</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IM</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">stat, then</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" |
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">200 mg </font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 2 weeks</font>
-|-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nikethamide  Nikethamide]</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Antidote for CNS-depressant drugs</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">7.8-31.2 mg/kg</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV, IM, SQ</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat, then as needed</font>
-|-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Nitenpyram]]</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Fleas]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1 tab</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">daily as needed</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nitrofurantoin  Nitrofurantoin]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Nitroglycerin 2% ointment</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Urinary tract infection</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5-4.0 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Prophylactic dose</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">4 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nitroglycerin  Nitroglycerin] 2% ointment</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Vasodilator for pre-load reduction</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1/8-1/4 inch (0.3-0.6cm)</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1/8 - 1/4 inch (0.3-0.6cm)</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">cutaneously</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nitroprusside  Nitroprusside] (vasodilator)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Nitroprusside</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Acute [[Congestive heart failure|CHF]]</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Acute [[Congestive heart failure]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5-10 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5-10 µg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 1 min</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Norepinephrine  Norepinephrine] bitartrate</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Norepinephrine</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Positive ionotrope</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.05-0.3 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.05 - 0.3 µg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 1 min</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Nortriptyline  Nortriptyline] (tricyclic antidepressant - noradrenaline reuptake inhibitor)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Novobiocin</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Behaviour disorders</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5-2.0 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Novobiocin Novobiocin]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Nystatin]]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Nystatin</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">100,000 IU</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Octreotide]] (Sandostatin)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Octreotide]] </font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Chylothorax]], [[Acromegaly]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1 mg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Ofloxacin]] (fluoroquinolone)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Ofloxacin</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5-10.0 mg/kg</font>
@@ Line 2,817: / Line 2,649: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Olsalazine  Olsalazine sodium]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Omeprazole]]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Diarrhoea|Inflammatory bowel disease]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10-20mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
-|-
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">Omega fatty acids</font>
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">see Derm caps</font>
-| width="18%" height="20" align="left" valign="top" |
-| width="20%" height="20" align="left" valign="top" |
-| width="20%" height="20" align="left" valign="top" |
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Omeprazole]] (Losec)</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Gastritis, gastric ulceration</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 mg/cat</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Ondansetron]] - 5-HT<sub>3</sub> receptor antagonists</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Ondansetron]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antiemetic</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5-1.0 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5 - 1.0 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Orbifloxacin]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5-7.5 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5 - 7.5 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Megestrol acetate|Ovarid]]</font>
@@ Line 2,853: / Line 2,673: @@
 | width="20%" height="18" align="left" valign="top" |
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxacillin  Oxacillin]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Oxymorphone</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">22-40 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxazepam  Oxazepam]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Appetite stimulant</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.0-2.5 mg/cat</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxtriphylline  Oxtriphylline]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Bronchodilator</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">6 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 -12hrs</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" |
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">10-15 mg/cat</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxybutynin Oxybutynin] (anticholinergic)</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Detrusor hyperspasticity</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/cat</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxymetholone  Oxymetholone]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anabolic agent</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Oxymorphone]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Preanaesthetic</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1-0.2 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1 - 0.2 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">with ACP or atropine</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxytetracycline  Oxytetracycline]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Oxytocin]]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Dystocia</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">55-82.5 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5 - 1.0 IU/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Bartonella henselae infection|Haemobartonella]]</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">20-40 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8hrs for 3 weeks</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxytocin  Oxytocin]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Acute metritis</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5-1.0 IU/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM, SQ</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 2hrs for max of 3 doses</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 2 hrs for max of 3 doses</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Paclitaxel  Paclitaxel] (mitotic inhibitor)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Paclitaxel]] </font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Chemotherapy]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 mg/kg</font>
@@ Line 2,919: / Line 2,691: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">pre-treat for anaphylaxis</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pancreatin  Pancreatic enzymes]</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Pancuronium bromide</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Exocrine pancreatic insufficiency]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1-2 tablets, 1-2 teaspoons</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">20 mins prior to food, bid</font>
-|-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Pancuronium  Pancuronium bromide]</font>
 | width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Paralytic agent for controlled anaesthesia</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.044-0.11 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.044 - 0.11 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV </font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Paregoric  Paregoric]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Atovaquone|Parvaquone]]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antidiarrhoeal</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Toxoplasma spp|Toxoplasmosis]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.05-0.06 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10 - 30 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Paromomycin  Paromomycin] (aminosidine)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[D-penicillamine]]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Cryptosporidium spp]]</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[chronic hepatitis]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">125-165 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10 - 15 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs for 5 days</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Paroxetine  Paroxetine] (SSRI)</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Behaviour modification</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1.25-2.5 mg/cat</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Atovaquone  Parvaquone]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Toxoplasma|Toxoplasmosis]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10-30 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">D- [http://en.wikipedia.org/wiki/Penicillamine  penicillamine]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Progressive hepatitis</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10-15 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Penicillin G</font>
@@ Line 2,967: / Line 2,715: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pentazocine  Pentazocine]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Pentazocine</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Analgesia]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.2-3.3 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.2 - 3.3 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM, SQ</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 4hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 4 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pentobarbital  Pentobarbital]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Pentobarbital]]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">General anaesthesia</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[general anesthesia]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">25-30 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">25 - 30 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">to effect</font>
@@ Line 2,981: / Line 2,729: @@
 | width="20%" height="20" align="left" valign="top" |
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy|Status epilepticus]]</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">5-15 mg/kg</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">5 - 15 mg/kg</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">to effect</font>
@@ Line 2,987: / Line 2,735: @@
 | width="20%" height="20" align="left" valign="top" |
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Sedation</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2-4 mg/kg</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2 - 4 mg/kg</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 6 hrs</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Cartrophen|Pentosan polysuphate]]</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Pentosan polysulfate]]</font>
 | width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Disease modifying agent, arthritis</font>
 | width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">3 mg/kg</font>
@@ Line 2,997: / Line 2,745: @@
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 7 days</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pentoxifylline  Pentoxifylline] (phosphodiesterase antagonist)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Pentoxifylline</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Dermatomyositis]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">100 mg/cat</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
 | width="20%" height="34" align="left" valign="top" |
 | width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Pemphigus|Autoimmune skin diseases]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">10-15 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">10 - 15 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Periactin</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Appetite stimulant</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1-4 mg/cat</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Petrolatum  Petrolatum], white</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Laxative</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1-5 ml/cat</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Phenamidine isethionate</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Feline babesiosis|Babesiosis]]</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">''[[Babesia spp]]''</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">7.5 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, SQ</font>
@@ Line 3,029: / Line 2,765: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Phenobarbital]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy|Status epilepticus]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5-5 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5 - 5 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO, IM, IV</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Phenoxybenzamine  Phenoxybenzamine HCl] (a-adrenergic antagonist)</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Phenoxybenzamine]]</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Hypertension|Acute hypertension]] from [[Pheochromocytoma]]</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Hypertension]], [[pheochromocytoma]]</font>
 | width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
 | width="20%" height="20" align="left" valign="top" |
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Bladder physiology|Detrusor areflexia]]</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2.5-10 mg/cat</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.5 - 2.0 mg/cat</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
 | width="20%" height="20" align="left" valign="top" |
@@ Line 3,057: / Line 2,793: @@
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Phentolamine  Phentolamine] (a-adrenergic antagonist)</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Phentolamine</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Hypertension]] from [[Pheochromocytoma]]</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[hypertension]] from [[pheochromocytoma]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.02-0.1 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.02 - 0.1 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Phenylephrine  Phenylephrine] (a-adrenergic agonist)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Phenylephrine</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Vasopressor, decongestant, mydriatic</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.15 mg/kg</font>
@@ Line 3,069: / Line 2,805: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">as needed</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Phenylpropanolamine  Phenylpropanolamine]</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Phenylpropanolamine</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Urethral sphincter incompetence</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[incontinence]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1.5-2.0 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1.5 - 2.0 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Phenytoin  Phenytoin]</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Phenytoin]]</font>
 | width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy|Seizures]], ventricular arrhythmias</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">2-3 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">2 - 3 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Phosphate (K or Na)</font>
@@ Line 3,087: / Line 2,823: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">over 6 hrs</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Physostigmine]] (Syrup)</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Physostigmine (Syrup)</font>
 | width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Myasthenia gravis]], [[Glaucoma]], magic-mushroom intoxication</font>
 | width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.25-5.0 mg/cat</font>
@@ Line 3,093: / Line 2,829: @@
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Physostigmine  Physostigmine] (0.5%)</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">Phytomenadione</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Dysautonomia|Feline dysautonomia]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">apply 1/8 inch</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">topically</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
-|-
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Phytomenadione  Phytomenadione]</font>
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">See Vitamin K1</font>
 | width="18%" height="20" align="left" valign="top" |
@@ Line 3,105: / Line 2,835: @@
 | width="20%" height="20" align="left" valign="top" |
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pilocarpine  Pilocarpine] 1% ophthalmic</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Pilocarpine 1% ophthalmic</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Dysautonomia]], [[glaucoma]]</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[glaucoma]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 drop</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">topically</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 hrs</font>
 |-
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Pimaricin]] (Pimaracin)</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">Pimaricin</font>
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Ocular fungal infections</font>
 | width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 drop</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">topically</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 3 - 8hrs</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 3 - 8 hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Piperacillin  Piperacillin] sodium</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">25-50 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Piperacillin  Piperacillin-tazobactum]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">25-50 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Piperazine  Piperazine]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Parasites|Helminths]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">44-66 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">repeat in 3 weeks</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Piroxicam  Piroxicam] (NSAID, non-selective COX inhibitor)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Piroxicam</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Analgesia]], [[Cancer|Neoplasia]]</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Analgesia]], [[Cancer|neoplasia]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.3 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 - 72hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 - 72 hrs</font>
 |-
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial"> http://en.wikipedia.org/wiki/Plicamycin  Plicamycin]</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">Plicamycin</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Hypercalcemia, testicular cancer, malignancies</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hypercalcemia]], testicular cancer, malignancies</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.25-0.50 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.25 - 0.50 µg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs x 2</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs x 2</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Polyethylene_glycol  Polyethylene glycol]</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Polyethylene glycol</font>
 | width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Lubricant, intestinal cathartic</font>
 | width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">25 ml/kg</font>
@@ Line 3,157: / Line 2,869: @@
 | width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">25 ml/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 2 - 4hrs</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 2 - 4 hrs</font>
 |-
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Polymixin B]]</font>
 | width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Sepsis]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
-|-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Glycosaminoglycans  Polysulfated glycosaminoglycans]</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Degenerative joint disease</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">2-5 mg/kg</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IM</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 3 - 5days</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Posaconazole]]</font>
@@ Line 3,184: / Line 2,890: @@
 |-
 | width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Hypokalemia</font>
+| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Hypokalemia]]</font>
 | width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.5 mEq/kg</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
@@ Line 3,191: / Line 2,897: @@
 | width="20%" height="20" align="left" valign="top" |
 | width="22%" height="20" align="left" valign="top" |
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1-3 mEq</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 - 3 mEq</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO. IV</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
 | width="20%" height="34" align="left" valign="top" |
@@ Line 3,208: / Line 2,914: @@
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Potassium gluconate</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hypokalemic polymyopathy]]</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hypokalemia]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5-8 mEq/cat</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5-8 mEq/dog</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Potassium iodide</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Sporotrichosis spp]], [http://en.wikipedia.org/wiki/Pythiosis  pythiosis]</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[fungal infections]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">30-100 mg/cat</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">6 - 20 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 10-14 days</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 10-14 days</font>
 |-
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Potassium permanganate (1:2000)</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Strychnine toxicosis</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Strychnine]] toxicosis</font>
 | width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">5 ml/kg in gastric lavage</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
@@ Line 3,235: / Line 2,941: @@
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">Apply light coating</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Topically</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Pradofloxacin]] ([[Fluoroquinolones|Fluoroquinolone]])</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Pradofloxacin]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Broad-spectrum antimicrobial</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 - 10 mg/kg</font>
@@ Line 3,243: / Line 2,949: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 7 days</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Pralidoxime  Pralidoxime chloride] (2-PAM)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Pralidoxime chloride]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Organophosphate toxicosis</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM, SQ</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Praziquantel]]</font>
@@ Line 3,256: / Line 2,962: @@
 |-
 | width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">''[[Platynosomum spp]]'', ''[[Paragonimus spp]]''</font>
+| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">''[[Paragonimus spp]]''</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">25-30 mg/kg</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">25 - 30 mg/kg</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 5-10 days</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Prazosin  Prazosin] (a<sub>1</sub>-adrenergic antagonist)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Prazosin]] </font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">After load reductions</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5-2.0 mg/cat</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5 - 2.0 mg/dog</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
 |-
 | width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Feline lower urinary tract disease (FLUTD)|Urethral obstruction]]</font>
+| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Cystitis]]</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.5-2.0 mg/cat (0.07mg/kg)</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.07 mg/kg</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Prednisolone]]</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Eosinophilic ulcers, plasma cell gingivitis</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">anti-inflammatory</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24hrs (each evening)</font>
-|-
-| width="20%" height="34" align="left" valign="top" |
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Plasmacytic lymphocytic enteritis</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12hrs, then taper dose weekly</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs (each evening)</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Urethritis, persistent </font><font size="2" face="Arial">hematuria</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2.5-5.0 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48hrs</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Anti-inflammatory</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2.2 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
 |-
 | width="20%" height="20" align="left" valign="top" |
@@ Line 3,301: / Line 2,989: @@
 | width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
-| width="20%" height="20" align="left" valign="top" |
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Prednisolone]] acetate</font>
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Chronic therapy</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2-4 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 48hrs</font>
-|-
-| width="20%" height="34" align="left" valign="top" |
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Pemphigus|Immune-mediated skin diseases]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1.1-2.2 mg/kg</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12hrs until remission, then taper</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[FIP]]</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">4 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs with cyclophosphamide</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Allergy</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO, IM</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Immunosuppression</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">3 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
-|-
-| width="20%" height="34" align="left" valign="top" |
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Lymphosarcoma]], myeloproliferative disorders</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Multiple myeloma]]</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Prednisolone acetate</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Addison's disease|Hypoadrenocorticism]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1-0.2 mg/kg</font>
@@ Line 3,387: / Line 3,033: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5ml q 24hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Primaquine]]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Procainamide</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Feline babesiosis]]</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Ventricular arrhythmias</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">62.5 mg/dog</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO, IM</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Procainamide  Procainamide]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Ventricular </font><font size="2" face="Arial">arrhythmias</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">62.5 mg/cat</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Prochlorperazine  Prochlorperazine]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Prochlorperazine</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antiemetic</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Antiemetic]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 hrs</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" |
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Promazine  Promazine hydrochloride]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Promazine hydrochloride</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Preanaesthetic</font>
+| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Pre-anaesthetic]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.2-6.6 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.2 - 6.6 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
@@ Line 3,423: / Line 3,057: @@
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 4 - 6hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Promethazine  Promethazine] HCl</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Promethazine HCl</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antihistamine, antiemetic</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.2-0.4 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.2 - 0.4 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM, PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8 hrs</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Propantheline_bromide  Propantheline bromide]</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Propantheline bromide</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Acute colitis, irritable bowel syndrome, antiemetic</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Acute [[colitis]], [[ulcerative colitis]], [[antiemetic]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.22-0.25 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.22 - 0.25 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8hrs up to 3 days</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs up to 3 days</font>
 |-
 | width="20%" height="34" align="left" valign="top" |
@@ Line 3,446: / Line 3,080: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
-|-
-| width="20%" height="50" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Propionibacterium_acnes  Propionibacterium acnes]</font>
-| width="22%" height="50" align="left" valign="top" | <font size="2" face="Arial">Immunostimulation, [feline%20leukemia.htm  FeLV associated disease], retrovirus infection</font>
-| width="18%" height="50" align="left" valign="top" | <font size="2" face="Arial">15 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
-| width="20%" height="50" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="50" align="left" valign="top" | <font size="2" face="Arial">biweekly for 2 - 3 weeks</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Propofol]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">General anaesthesia, [[status epilepticus]]</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">Induction: 6-8 mg/kg</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">Induction: 6 - 8 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
@@ Line 3,471: / Line 3,099: @@
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q min</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Propranolol]] (ß-adrenergic antagonist)</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Propranolol]]</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Ventricular hypertrophy, aortic stenosis, [[hypertrophic cardiomyopathy|HCM]]</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Ventricular hypertrophy, [[aortic stenosis]], [[hypertrophic cardiomyopathy|HCM]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.4-1.2 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.4 - 1.2 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
 | width="20%" height="20" align="left" valign="top" |
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Ventricular arrhythmias</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.02-0.06 mg/kg</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.02 - 0.06 mg/kg</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">over 2-3 min; q 8hrs</font>
@@ Line 3,491: / Line 3,119: @@
 | width="20%" height="20" align="left" valign="top" |
 | width="22%" height="20" align="left" valign="top" |
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2.5-5.0 mg</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2.5 - 5.0 mg</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
@@ Line 3,503: / Line 3,131: @@
 | width="20%" height="20" align="left" valign="top" |
 | width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Hypertension</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2.5-5.0 mg/cat</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2.5 - 5.0 mg/cat</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
 | width="20%" height="34" align="left" valign="top" |
@@ Line 3,513: / Line 3,141: @@
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Propylthiouracil]] (PTU)</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Propylthiouracil (PTU)</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hyperthyroidism]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 |-
 | width="20%" height="20" align="left" valign="top" |
 | width="22%" height="20" align="left" valign="top" |
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">50 mg/cat</font>
+| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Prostaglandin  Prostaglandin] F2 alpha</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Prostaglandin]] F2 alpha</font>
-| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Pyometra]], [[Endometrial hyperplasia|Cystic endometrial hyperplasia]]</font>
+| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Pyometra]], [[Cystic endometrial hyperplasia]]</font>
-| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.10-0.25 mg/kg</font>
+| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.10 - 0.25 mg/kg</font>
 | width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
-| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 3-5 days</font>
+| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 3 - 5 days</font>
 |-
 | width="20%" height="34" align="left" valign="top" |
@@ Line 3,545: / Line 3,173: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Pseudoephedrine]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Nasal decongestant</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">15-30 mg/cat</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">15 - 30 mg/dog</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
@@ Line 3,555: / Line 3,183: @@
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Psyllium  Psyllium]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Psyllium</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Bulk laxative</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1-3 tsp</font>
+| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 - 3 tsp</font>
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Pyrantel_pamoate  Pyrantel pamoate]</font>
@@ Line 3,567: / Line 3,195: @@
 | width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">repeat in 2 weeks</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pyridostigmine  Pyridostigmine bromide]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Pyridostigmine bromide]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Myasthenia gravis]](acquired)</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1-5 mg</font>
@@ Line 3,584: / Line 3,212: @@
 | width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 | width="20%" height="20" align="left" valign="top" |
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Pyrilamine  Pyrilamine maleate]</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antihistamine</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">12.5-25.0 mg/cat</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pyrimethamine  Pyrimethamine]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Malaria  Malaria], Neosporosis</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.25-1.0 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
@@ Line 3,609: / Line 3,225: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 14 - 28 days</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Quinacrine  Quinacrine]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Quinacrine</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Giardia spp]], [[Coccidiosis]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">''[[Giardia spp]]'', [[Coccidiosis]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">11 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 5 days</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 5 days</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial"> [[Ranitidine]] (Zantac)</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial"> [[Ranitidine]]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">H-2 receptor antagonist for use in gastritis, GI tract ulceration</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[gastritis]], GI tract ulceration</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV, PO, SQ</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypergastrinemia associated with chronic renal insufficiency</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">3.5 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Retinol  Retinol] (Vit A)</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Retinol]]</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Dermatological lesions</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">625-800 IU/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">625 - 800 IU/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Ribavirin  Ribavirin]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible viral infections</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">11 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, IM, IV</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 7 days</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Riboflavin  Riboflavin] (Vit B12)</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Bartonella henselae infection|Bartonellosis]] (with doxycycline)</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5-10 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 14days</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Rifampicin]]</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10-20 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10 - 20 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
@@ Line 3,653: / Line 3,251: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Ringer's solution</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Maintenance solution</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">40-50 ml/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">40 - 50 ml/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV, SC, IP</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
@@ Line 3,661: / Line 3,259: @@
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">30 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 14 days</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 14 days</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">(warning: low therapeutic margin)</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q12hrs for 14 days</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs for 14 days</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Roxithromycin  Roxithromycin]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Roxithromycin</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Rutin]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Secnidazole]]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[FIP|Chylothorax]], limb lymphedema </font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">50 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Secnidazole]]</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Giardia spp]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">30 mg/kg</font>
@@ Line 3,687: / Line 3,279: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Deprenyl|Selegiline]] (Fitergol)</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Selegiline]]</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Cognitive disorders]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Cushing's syndrome|Hyperadrenocorticism]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[hyperadrenocorticism]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Selamectin]]</font>
@@ Line 3,729: / Line 3,321: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfadiazine]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfadiazine</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Burns</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">Apply light coating</font>
@@ Line 3,775: / Line 3,367: @@
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">40-50 ml/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV, SQ, IP</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sodium iodide, 20% soln</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sporotrichosis spp]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5 ml/5kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 |-
@@ Line 3,787: / Line 3,373: @@
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 4 - 6 wks</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 4 - 6 wks</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sodium phosphate</font>
@@ Line 3,794: / Line 3,380: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 24hrs until stools are soft</font>
-|-
-| width="20%" height="10" align="left" valign="top" |
-<font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Polystyrene_sulfonate  Sodium polystyrene ]</font> [http://en.wikipedia.org/wiki/Polystyrene_sulfonate  <font size="2" face="Arial">sulphonate</font>]
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypercalcemia</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">8-15 g/cat</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Thiopentone|Sodium thiopental]]</font>
@@ Line 3,808: / Line 3,387: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">to effect</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sorafenib]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sorafenib</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Chemotherapy]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2 mg/kg</font>
@@ Line 3,820: / Line 3,399: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sotalol]] ([[Adrenergic antagonists|ß-adrenoceptor antagonist]])</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sotalol</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Ventricular arrhythmias</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Spectinomycin]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Spectinomycin</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5-12 mg/kg</font>
@@ Line 3,832: / Line 3,411: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Spiramycin]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Spiramycin</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Toxoplasma|Toxoplasmosis]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">''[[Toxoplasma spp]]''</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">12.5-23 mg/cat</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">12.5 - 23 mg/dog</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Spironolactone]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Spironolactone</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Diuretic: heart failure</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2-4 mg/kg</font>
@@ Line 3,845: / Line 3,424: @@
 |-
 | width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Conn's syndrome|Primary hyperaldosteronism]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Hyperaldosteronism]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
@@ Line 3,852: / Line 3,431: @@
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hepatic insufficiency</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">12.5 mg/cat</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">3.0 - 4.0 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Spironolactone]] / hydrochlorothiazide</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Spironolactone / hydrochlorothiazide</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Diuretic, antihypertensive agent</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Diuretic]], antihypertensive agent</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12-24hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Stanozolol  Stanozolol]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Stanozolol]]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anabolic agent, </font><font size="2" face="Arial">anaemia</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anabolic agent, [[anemia]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/cat</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/dog</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" |
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10-25 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10 - 25 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 7days</font>
@@ Line 3,876: / Line 3,455: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Staphage lysate</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Immune stimulant</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1-0.2 ml/cat</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1 - 0.2 ml/cat</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">then</font>
@@ Line 3,892: / Line 3,471: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">weekly for 10 - 12 weeks</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Staphylococcal infections|Staphylococcal A]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Staphylococcus spp|Staphylococcal A]]</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Immune stimulant</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/2.75kg</font></span>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 µg/2.75kg</font></span>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IP</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 3 - 5 days</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Streptomycin]], dihydro</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Streptomycin, dihydro</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Leptospirosis]], endocarditis, ''[[Mycobacterium spp]]'', ''[[Yersinia pestis]]''</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Leptospirosis]], [[endocarditis]], ''[[Mycobacterium spp]]'', ''[[Yersinia pestis]]''</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q6hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 6 hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Styrid caricide (styrylpyridium chloride plus diethylcarbamazine)</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Succinylcholine</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antiparasiticide</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">6.7mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Succinylcholine  Succinylcholine]</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Paralysis</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.06-0.11 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.06 - 0.11 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sucralfate]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sucralfate</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Gastrointestinal ulceration</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">250-500 mg/cat</font>
@@ Line 3,926: / Line 3,499: @@
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">40 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sufentanil]] (opioid agonist)</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfadiazine</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Premedicant with ACP</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg (max dose 5 µg/kg)</font></span>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfadiazine]]</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Nocardiosis</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">220 mg/kg</font>
@@ Line 3,944: / Line 3,511: @@
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">50-110 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Toxoplasma|Toxoplasmosis]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Toxoplasma spp|Toxoplasmosis]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15-50 mg/kg (with pyrimethamine)</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 - 50 mg/kg (with pyrimethamine)</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, divided, for 14 days</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs, divided, for 14 days</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Trimethoprim/Sulphonamides|Sulfadiazine/Trimethoprim]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Trimethoprim/Sulphonamides]]</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">30 mg/kg</font>
@@ Line 3,959: / Line 3,526: @@
 |-
 | width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Meningitis</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Meningitis]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, IV</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Nocardiosis</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">30-60 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">30 - 60 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, SQ</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfadimethoxine]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfadimethoxine</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">25-50 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">25 - 50 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, IM, IV</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs for max of 21days</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs for max of 21 days</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
@@ Line 3,988: / Line 3,555: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfamethazine]], sulfamerazine</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfamethazine, sulfamerazine</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Coccidiosis]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">200 mg/kg (loading), then 50 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfamethoxazole]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfamethoxazole</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">100 mg/kg (loading), then 50 mg/kg</font>
@@ Line 4,000: / Line 3,567: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfamethoxazole]]/[[Trimethoprim]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfamethoxazole/Trimethoprim</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
@@ Line 4,007: / Line 3,574: @@
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfasalazine]]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[irritable bowel disease|Lymphocytic plasmacytic enteritis]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[ulcerative colitis]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">250 mg/cat</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
@@ Line 4,013: / Line 3,580: @@
 |-
 | width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Irritable bowel disease]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[ulcerative colitis]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20-25 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 -24hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 -24 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
@@ Line 4,024: / Line 3,591: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Sulfisoxazole  Sulfisoxazole]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfisoxazole</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Urinary tract infections</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[cystitis]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">50 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfobromophthalein sodium</font>
@@ Line 4,036: / Line 3,603: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">collect serum 30 min after BSP injection</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Suprofen  Suprofen ophthalmic]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Suprofen ophthalmic</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Allergic conjunctivitis</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Allergic [[conjunctivitis]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1%</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Topically</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tacrolimus]]</font>
@@ Line 4,048: / Line 3,615: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Tamiflu  Tamiflu]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Telazol</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Viral disease</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2-4 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs within 48hrs of infection</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Taurine</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Taurine deficiency]], [[Cardiomyopathy - dilated|dilated cardiomyopathy]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">250-500 mg/cat</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Central retinal degeneration</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">250 mg/cat</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Telazol  Telazol] (Zoletil - Tiletamine / zolazepam)</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Restraint</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">6.6 mg/kg</font>
@@ Line 4,073: / Line 3,622: @@
 |-
 | width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anaesthesia</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Anesthesia]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">11-15 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">11 - 15 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Temaril-P (Trimeprazine and prednisolone)</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Terbinafine]]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Allergy</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.7-1.1 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Lamisil|Terbinafine]] (Lamasil)</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Fungal infections]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 - 30 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 4 - 10 wks</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 4 - 10 wks</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Terbutaline sulphate]] ([[adrenergic antagonists|ß<sub>2</sub>-adrenoceptor agonist]])</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Terbutaline]] sulphate</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Bronchodilator</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.01 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ, IM</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 4hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 4 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" |
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1.25-2.5 mg/cat</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1.25 - 2.5 mg/cat</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
@@ Line 4,108: / Line 3,651: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 2 - 3 days</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Testosterone, methyl</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Testosterone]], methyl</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anabolic effects</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg; max 30 mg/day</font>
@@ Line 4,121: / Line 3,664: @@
 |-
 | width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Urinary incontinence</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[incontinence]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5-10 mg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5 - 10 mg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
@@ Line 4,128: / Line 3,671: @@
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" |
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5-1.0 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5 - 1.0 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 2 - 3 days</font>
@@ Line 4,138: / Line 3,681: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">watch for anaphylaxis for 30 min</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tetracycline]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Tetracycline</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Acute bronchitis</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10-25 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10 - 25 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12krs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Rickettsia spp]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">''[[Rickettsia spp]]''</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8hrs for 21 days</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs for 21 days</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
@@ Line 4,158: / Line 3,701: @@
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-5 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 5 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV, IM</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Methylxanthines|Theophylline]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Theophylline</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Bronchodilator</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, IM</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Theo-Dur (Sustained release)</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Bronchodilator</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20-25 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 - 25 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, at night</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs, at night</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Thiabendazole  Thiabendazole]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thiabendazole</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Heartworm disease]] adulticide</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">35 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs for 20 days</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs for 20 days</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Strongyloides</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">''[[Strongyloides spp]]''</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">125 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 3 days</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 3 days</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thiacetarsamide</font>
@@ Line 4,190: / Line 3,733: @@
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2.2 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs for 2 days</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs for 2 days</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thiamine (Vit B12)</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thiamine</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Thiamine deficiency]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/cat</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/dog</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs until regression of symptoms</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs until regression of symptoms</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" |
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">100-250 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">100 - 250 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thiamylal sodium</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anaesthesia</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">8.8-13.3 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">8.8 - 13.3 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">after tranquilisation</font>
@@ Line 4,217: / Line 3,760: @@
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thyroid</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypothyroidism</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Hypothyroidism]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15-20 mg/kg/day</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 - 20 mg/kg/day</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Thiopentone]]</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">General anaesthesia, [[status epilepticus]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">3-15 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">3 - 15 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">to effect</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Thyrotropin Thyrotropin] (TSH)</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thyrotropin</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Provocative testing</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 IU/kg</font>
@@ Line 4,235: / Line 3,778: @@
 |-
 | width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Acanthosis nigrans, hypothyroidism</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Acanthosis nigrans]], [[hypothyroidism]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 IU</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 2 IU</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 5 days</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 5 days</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">L-Thyroxine (levothyroxine)</font>
@@ Line 4,248: / Line 3,791: @@
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" |
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20-30 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 - 30 µg/kg</font></span>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Ticarcillin  Ticarcillin]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Ticarcillin</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">33-50 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">33 - 50 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8kg</font>
@@ Line 4,272: / Line 3,815: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Tiletamine / zolazepam</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Minor procedure</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">9.7-11.9 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">9.7 - 11.9 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
@@ Line 4,278: / Line 3,821: @@
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Castration</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10.6-12.5 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10.6 - 12.5 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">do not exceed 72mg/kg with repeat doses</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">do not exceed 72 mg/kg with repeat doses</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Spey</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">14.3-15.8 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">14.3 - 15.8 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tinidazole]]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Gingivitis]], ''[[Giardia spp]]''</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">30 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 14 days</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Tiopronin Tiopronin]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Cystine urinary calculi</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15-20 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Tolazoline</font>
@@ Line 4,306: / Line 3,837: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tolfenamic acid]] (Tolfedine)</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tolfenamic acid]] </font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Analgesia]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4 mg/kg</font>
@@ Line 4,314: / Line 3,845: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Toltrazuril]] (Baycox)</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Coccidiosis]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5-20 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5 - 20 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs x 2-5 treatments</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs x 2 - 5 treatments</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Toluene  Toluene]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Toluene</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anthelmintic</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">267 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">repeat in 2-4 weeks</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">repeat in 2 - 4 weeks</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tramadol]]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Opioids|Opioid]] [[analgesia]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Opioid [[analgesia]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" |
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">12.5 mg/cat</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">12.5 mg/dog</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Tretinoin</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Acne]], nasal hyperkeratosis</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.25-0.5 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 7 days</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Triamcinolone]]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Gingivitis]], pododermatitis</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Gingivitis]], [[pododermatitis]], [[acral lick granuloma]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2-4 mg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2 - 4 mg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Hypokalemic polymyopathy]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Pannus, [[episcleritis]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5-1.0 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antiinflammatory</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.11-0.22 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM, SQ</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
-|-
-| width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Pannus, eosinophilic keratitis, episcleritis</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4 mg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Subconjunctival</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 |-
-| width="20%" height="10" align="left" valign="top" |
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Triamterene</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Esophageal stricture</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/cat</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">submucosal</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
-|-
-| width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Glucocorticoid effect</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1-0.2 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM, SQ</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Triamterene  Triamterene]</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Diuretic</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Trientine hydrochloride</font>
@@ Line 4,388: / Line 3,889: @@
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10-15 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Triethylene thiophosphoramide</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Bladder neoplasia</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">30 mg/m<sup>2</sup></font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Intravesicular</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 3 - 4wks</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Thiethylperazine  Thiethylperazine]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antipsychotic</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.13-0.2 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Trifluoperazine  Trifluoperazine]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antipsychotic</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.03 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Triflupromazine  Triflupromazine]</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Behaviour modification</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1-0.3 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1 - 0.3 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM, PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Trifluridine  Trifluridine ophthalmic]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[FHV|herpes infection]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1% soln, 1-2 drops</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Topically</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 34 - 8hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Triiodothyronine  Triiodothyronine] (T3)</font>
@@ Line 4,438: / Line 3,915: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Tripelennamine  Tripelennamine]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Tripelennamine</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antihistamine</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, IM</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Trypan_blue  Trypan blue]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Trypan blue</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Feline babesiosis]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">''[[Babesia spp]]''</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
@@ Line 4,468: / Line 3,945: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Urokinase]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Urokinase</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Aortic thromboembolism]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[thromboembolism]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">90,000 IU over 20 minutes, then 45,000 IU CRI</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">for up to 24 hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Urofollitropin  Urofollitropin]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Urofollitropin</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypogonadotropic anovulation</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2 mg/cat</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2 mg/dog</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Ursodeoxycholic acid]]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Feline inflammatory liver disease|Chronic hepatitis]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[chronic hepatitis]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5-15 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Valproic_acid  Valproic acid]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Valproic acid</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">25-65 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">25 - 65 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">with </font><font size="2" face="Arial">Phenobarbital</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">with </font><font size="2" face="Arial">[[Phenobarbital]]</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
@@ Line 4,522: / Line 3,999: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">over 30 min</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Verapamil]] (calcium channel blocker)</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Verapamil]] </font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Supraventricular arrhythmias</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10-15 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10 - 15 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, divided</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs, divided</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
@@ Line 4,533: / Line 4,010: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Vidarabine]]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Ocular herpesviral infection</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1/8 inch</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Topically</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Vinblastine]]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Mast cell tumour]], [lymphosarcoma.htm  LSA]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Mast cell tumour]], [[lymphoma]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1-0.4 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1 - 0.4 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q7-14 days</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 7 - 14 days</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Vincristine]]</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Thrombocytopenia]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.01-0.025 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.01 - 0.025 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 7-10 days</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 7 - 10 days</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
@@ Line 4,560: / Line 4,031: @@
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Neoplasia</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5-0.75 mg/m<sup>2</sup></font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5 - 0.75 mg/m<sup>2</sup></font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 7 - 14days</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 7 - 14 days</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Viokase]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Viokase</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Exocrine pancreatic insufficiency]]</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">325 mg</font>
@@ Line 4,600: / Line 4,071: @@
 | width="20%" height="10" align="left" valign="top" |
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin D (dihydrotachysterol)</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin D</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypocalcemia</font>
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.02 mg/kg</font>
@@ Line 4,610: / Line 4,081: @@
 | width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.01 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin D2 (ergocalciferol)</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypocalcemia</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4000-6000 U/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4000 - 6000 U/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, initially, then</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs, initially, then</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" |
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">500-1000 U/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">500 - 1000 U/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin D3 (calcitriol - 1-25, dihydroxy vitamin D3)</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypocalcemia</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Hypocalcemia]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.03-0.06 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.03-0.06 µg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Chronic renal disease]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.025 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.025 µg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin E</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin E deficient myositis, [yellow%20fat%20disease.htm  steatitis]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[myopathy]], [[myocarditis]], [[retinal pigment epithelial dystrophy]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10-20 IU/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10 - 20 IU/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Pemphigus|autoimmune skin diseases]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Pemphigus]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">400-600 IU/cat</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">400 - 600 IU/dog</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin K1</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Deficiency, hepatopathy</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-3mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 3mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ, PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs for 4 - 6 weeks</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs for 4 - 6 weeks</font>
 |-
 | width="20%" height="10" align="left" valign="top" |
@@ Line 4,660: / Line 4,131: @@
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, divided doses</font>
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Voriconazole]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Warfarin</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Aspergillosis]]</font>
+| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[thromboembolism]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.06 - 0.20 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs. May cause neurotoxicity</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs. Maintain PTT at 2 - 2.5 times normal</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Warfarin  Warfarin]</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Aortic thromboembolism]]</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.06-0.20 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs. Maintain PTT at 2 - 2.5 times normal</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Xylazine]]</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Muscle relaxation</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1.1-2.2mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1.1 - 2.2mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM, SQ</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
@@ Line 4,684: / Line 4,149: @@
 | width="20%" height="10" align="left" valign="top" |
 |-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Zafirlukast]]</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Zafirlukast</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Leukotriene receptor antagonist</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.15-0.2mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.15 - 0.2mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
+| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs</font>
-|-
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Zidovudine]] (AZT)</font>
-| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antiviral</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5-20 mg/kg</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ, PO</font>
-| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 |-
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Zinc</font>
 | width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antioxidant</font>
-| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2-3 mg/kg</font>
+| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2 - 3 mg/kg</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 | width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 |-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Azithromycin|Zithromax]] (Azithromycin)]</font>
+| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Zonisamide</font>
-| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
-| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 mg/kg</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48 hrs</font>
-|-
-| width="20%" height="20" align="left" valign="top" |
-| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
-| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">80 mg stat</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
-| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">weekly x 3</font>
-|-
-| width="20%" height="10" align="left" valign="top" |
-| width="22%" height="10" align="left" valign="top" |
-| width="18%" height="10" align="left" valign="top" |
-| width="20%" height="10" align="left" valign="top" |
-| width="20%" height="10" align="left" valign="top" |
-|-
-| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Zonisamide]]</font>
 | width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy]]</font>
 | width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 mg/kg</font>